ASCP Corner: Why Aren't MAOIs Used More Often?
J Clin Psychiatry 2009;70(1):139-140
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
While I have spent most of my last 45 years in psychiatry
working in an academic setting and doing clinical research, I
have always had an active practice focused on major affective
disorders, especially treatment-resistant or treatment-refractory
cases. It is my impression that monoamine oxidase inhibitors
(MAOIs) are currently underutilized in the clinical practice of
psychiatry. Very few of the treatment-resistant patients that I
see have received a serious trial of MAOI therapy.